We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+9.51%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,043.31%
AUM
$470M
AUM Growth
+$131M
Cap. Flow
+$31.7M
Cap. Flow %
6.73%
Top 10 Hldgs %
48.76%
Holding
67
New
21
Increased
15
Reduced
13
Closed
12
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.4 years

Sector Composition

Rank Sector Weight
1 Healthcare 79.85%
2 Miscellaneous 20.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.5B
$47.9M 10.19%
500,000
+495,000
+9,900% +$48M
2016 Q1
10 quarters
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.43B
$33.9M 7.21%
210,000
+35,000
+20% +$4.78M
2018 Q1
2 quarters
PTCT icon
3
PTC Therapeutics
PTCT
$4.71B
$23.5M 5%
500,000
-175,000
-26% -$7.24M
2018 Q1
2 quarters
MRTX
4
DELISTED
Mirati Therapeutics
MRTX
$20.5M 4.36%
435,300
-64,700
-13% -$3.6M
2017 Q4
3 quarters
ECYT
5
DELISTED
Endocyte
ECYT
$19.5M 4.15%
1,100,000
+600,000
+120% +$10.3M
2018 Q1
2 quarters
IMMU
6
DELISTED
Immunomedics
IMMU
$18.4M 3.91%
883,823
-366,177
-29% -$8.67M
2016 Q2
9 quarters
TSRO
7
DELISTED
Tesaro
TSRO
$17.6M 3.73%
+450,000
New +$15.9M
2018 Q3
0 quarters
DRNA
8
DELISTED
Dicerna Pharmaceuticals
DRNA
$16.8M 3.57%
1,100,000
+440,000
+67% +$6.4M
2017 Q4
3 quarters
ASND icon
9
Ascendis Pharma
ASND
$16.6B
$15.9M 3.39%
225,000
+50,000
+29% +$3.44M
2017 Q3
4 quarters
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$19.3B
$15.3M 3.26%
175,000
-35,000
-17% -$3.52M
2018 Q2
1 quarter
MRTX
11
PUT
DELISTED
Mirati Therapeutics
MRTX
$14.1M 3%
+300,000
New +$16.7M
2018 Q3
0 quarters
FXF icon
12
Invesco CurrencyShares Swiss Franc Trust
FXF
$361M
$12.3M 2.61%
+128,700
New +$12.3M
2018 Q3
0 quarters
ASMB icon
13
Assembly Biosciences
ASMB
$454M
$12.1M 2.57%
27,083
+7,500
+38% +$3.51M
2018 Q1
2 quarters
BLUE icon
14
DELISTED
bluebird bio
BLUE
$11M 2.33%
3,750
-1,500
-29% -$4.78M
2018 Q2
1 quarter
ACAD icon
15
CALL
Acadia Pharmaceuticals
ACAD
$2.96B
$10.4M 2.21%
+500,000
New +$7.87M
2018 Q3
0 quarters
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$2.96B
$10.4M 2.21%
500,000
-35,000
-7% -$551K
2018 Q1
2 quarters
TVTX icon
17
Travere Therapeutics
TVTX
$4.51B
$10.1M 2.14%
+350,000
New +$10M
2018 Q3
0 quarters
ZGNX
18
DELISTED
Zogenix
ZGNX
$9.9M 2.11%
+200,000
New +$10.2M
2018 Q3
0 quarters
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$218M
$9.8M 2.09%
400,000
+50,000
+14% +$1.08M
2017 Q4
3 quarters
OBSV
20
DELISTED
ObsEva
OBSV
$9.6M 2.05%
535,000
+135,000
+34% +$1.98M
2017 Q4
3 quarters
ARGX icon
21
argenx
ARGX
$58.2B
$9.48M 2.02%
125,000
-25,000
-17% -$2.22M
2017 Q2
5 quarters
LRMR icon
22
Larimar Therapeutics
LRMR
$329M
$8.77M 1.86%
62,500
+53,978
+633% +$6.55M
2018 Q2
1 quarter
PTLA
23
DELISTED
Portola Pharmaceuticals
PTLA
$7.99M 1.7%
+300,000
New +$9.8M
2018 Q3
0 quarters
TCDA
24
DELISTED
Tricida
TCDA
$7.64M 1.62%
250,000
+63,981
+34% +$1.88M
2018 Q2
1 quarter
BHVN icon
25
DELISTED
Biohaven Pharmaceutical Holding
BHVN
$7.51M 1.6%
+200,000
New +$7.36M
2018 Q3
0 quarters

Similar funds

Ghost Tree Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Ghost Tree Capital held 67 positions worth $470M, up 38% from $340M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ghost Tree Capital deployed $31.7M of net new capital in Q3 2018, opening 21 new positions and adding to 15 existing holdings. Its largest new stake was Tesaro: 450,000 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Global Blood Therapeutics, an estimated $10.2M trimmed.

  • Ghost Tree Capital's largest Q3 2018 buy was Tesaro: 450,000 shares worth $17.6M.
  • Ghost Tree Capital added most to Endocyte in Q3 2018, an estimated $10.3M increase.
  • Ghost Tree Capital's biggest Q3 2018 reduction was Global Blood Therapeutics, cutting an estimated $10.2M.
  • Ghost Tree Capital fully exited Mersana Therapeutics in Q3 2018, selling an estimated $10.7M.
  • Ghost Tree Capital's ten largest holdings make up 49% of its $470M portfolio in Q3 2018.
  • Ghost Tree Capital opened 21 new positions and closed 12 in Q3 2018.
  • Ghost Tree Capital's portfolio value rose 38% quarter-over-quarter to $470M.

Based on Ghost Tree Capital's 13F filing for Q3 2018, filed 14 Nov 2018.